Skip to main content
. 2019 May 17;105(2):387–397. doi: 10.3324/haematol.2019.219394

Figure 6.

Figure 6.

Ponatinib rescues BCR-ABL1p210 driven eye defect. Scanning electron micro-graphs of adult Drosophila compound eyes from flies fed on 0.3% DMSO only or ponatinib. Posterior is to the left. GMR-GAL4>w1118 were used as control. E-H and M-P are high magnification of the posterior end of the eye in A-D and I-L respectively (692x). Normal development in control flies fed on DMSO or ponatinib is observed. BCR-ABL1p210 (C, G) and BCR-ABL1p210/T315I (K, O) expressing flies fed on DMSO show characteristic defective area with loss of ommatidial facets. Area is marked with a representative dashed line. Ommatidial development in this area was restored with BCR-ABL1p210 flies fed on ponatinib (D, H). Compare to (C, G). BCR-ABLp210/T315I flies showed no restoration of ommatidial development (L, P). Compare to (K, O). Lower left panel represents measurement of the posterior eye defect area (mm2). Data represents mean ± SEM. ****, P<0.0001. Lower right panel is a representative Western blot of the expression of BCR-ABL1 and phosphorylated levels in transgenic untreated and treated adult fly heads. Genotypes indicated are under the control of eye specific promoter GMR-GAL4.